About Aclaris Therapeutics, Inc. - Common Stock (ACRS)
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for dermatological and immunological diseases. The company is committed to addressing unmet medical needs by leveraging its expertise in drug development and dermatology to create novel treatment options. Aclaris's research portfolio includes a range of potential therapies aimed at conditions such as alopecia areata and other skin disorders, utilizing both small molecules and biologics to enhance patient care and improve quality of life. Through its dedication to scientific advancement and patient-centered approaches, Aclaris strives to make a meaningful impact in the field of dermatology. Read More
Aclaris Therapeutics Inc (NASDAQ: ACRS) surgged 21.94% in after-hours trading on Tuesday after positive top-line results from its open-label Phase 2a trial.
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Explore December 23's top pre-market picks, macro insights, and Santa Rally opportunities with StoryTrading's 4-pillar strategy. Join the community for exclusive trade ideas!
HC Wainwright upgraded Aclaris Therapeutics (ACRS) to Buy with a $20 price target. Aclaris gains after licensing agreement with Biosion for potential best-in-class therapies for atopic dermatitis and asthma.
Beaten-down stocks offer value to investors, but not all are worth buying. This is a look at three biopharma at long-term lows with catalysts for higher prices.
